Reumedika s.c.
- Address
- lock Available on a paid plan
Reumedika s.c. - Osteoarthritis Research Center
Reumedika s.c. is a specialized clinical research facility dedicated to advancing treatments for musculoskeletal disorders, with a particular emphasis on degenerative joint conditions. The center focuses on evaluating innovative therapeutic interventions aimed at addressing the structural and symptomatic aspects of chronic joint diseases.
- Structural modification therapies for knee osteoarthritis
- Novel biologics and regenerative medicine approaches
- Long-term safety and efficacy evaluation in symptomatic joint conditions
The research team at Reumedika specializes in comprehensive assessment protocols for osteoarthritis patients, utilizing advanced imaging techniques to measure structural changes in the tibiofemoral compartment. Their clinical trial portfolio demonstrates expertise in managing extended study durations and evaluating both disease-modifying interventions and patient-reported outcomes in individuals suffering from symptomatic knee conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1MoonLake Immunotherapeutics AG2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1MoonLake Immunotherapeutics AG3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Reumedika s.c.
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | MoonLake Immunotherapeutics AG | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sonelokimab | 3 | Unknown | 2025-03-25 | 2025-03-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.